See more : Trainline Plc (TNLIY) Income Statement Analysis – Financial Results
Complete financial analysis of Vivesto AB (OASMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivesto AB, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Advanced Micro Devices, Inc. (AMD.DE) Income Statement Analysis – Financial Results
- Organization of Football Prognostics S.A. (GOFPY) Income Statement Analysis – Financial Results
- Gresham House Strategic plc (GHS.L) Income Statement Analysis – Financial Results
- China Index Holdings Limited (CIH) Income Statement Analysis – Financial Results
- Adeia Inc. (ADEA) Income Statement Analysis – Financial Results
Vivesto AB (OASMY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.vivesto.com
About Vivesto AB
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02M | 26.19M | 201.84M | 201.84M | 1.98M | 3.17M | 172.00K | 6.37M | 2.07M | 60.00K | 0.00 | 891.00K | 106.00K | 30.74M | 79.36M | 71.16M | 22.39M | 853.22K | 11.00 |
| Cost of Revenue | 11.67M | 44.12M | -14.00M | -14.00M | -3.81M | -4.75M | -2.63M | -21.50M | -6.74M | -22.63M | -42.50M | -53.16M | -69.93M | -61.80M | 20.53M | 35.64M | 8.19M | -5.07M | -3.54M |
| Gross Profit | -10.66M | -17.93M | 215.85M | 215.85M | 5.79M | 7.92M | 2.81M | 27.88M | 8.81M | 22.69M | 42.50M | 54.05M | 70.04M | 92.54M | 58.82M | 35.52M | 14.20M | 5.93M | 3.54M |
| Gross Profit Ratio | -1,049.85% | -68.46% | 106.94% | 106.94% | 292.58% | 250.02% | 1,631.40% | 437.41% | 425.36% | 37,815.00% | 0.00% | 6,065.77% | 66,070.75% | 301.04% | 74.12% | 49.92% | 63.41% | 694.43% | 32,168,400.00% |
| Research & Development | 0.00 | 0.00 | 88.59M | 0.00 | 57.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 79.44M | 0.00 | 0.00 | 69.68M | 60.24M | 79.90M | 98.10M | 60.74M | 75.19M | 65.02M | 41.14M | 37.37M | 29.41M | 25.66M | 17.53M | 10.56M | 5.85M | 3.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 79.44M | 184.72M | 0.00 | 69.68M | 60.24M | 79.90M | 98.10M | 60.74M | 75.19M | 65.02M | 41.14M | 37.37M | 29.41M | 25.66M | 17.53M | 10.56M | 5.85M | 3.90M |
| Other Expenses | 355.72M | 34.15M | 0.00 | 246.25M | 83.41M | 51.57M | 63.59M | 62.47M | 56.36M | 49.84M | 47.39M | 78.44M | 97.02M | 78.09M | 76.38M | 32.52M | 27.47M | 17.50M | 8.12M |
| Operating Expenses | 355.72M | 113.59M | 246.25M | 246.25M | 125.93M | 111.65M | 143.49M | 160.57M | 117.10M | 125.03M | 112.41M | 119.58M | 134.39M | 107.51M | 102.04M | 50.05M | 38.03M | 23.35M | 12.01M |
| Cost & Expenses | 367.39M | 157.71M | 232.25M | 232.25M | 122.11M | 106.89M | 140.86M | 139.07M | 110.36M | 102.40M | 69.91M | 66.43M | 64.46M | 45.70M | 122.57M | 85.69M | 46.22M | 18.28M | 8.48M |
| Interest Income | 20.00K | 1.17M | 1.17M | 1.17M | 19.00K | 101.00K | 85.00K | 1.00K | 170.00K | 176.00K | 555.00K | 331.00K | 484.00K | 411.00K | 0.00 | 0.00 | 21.00K | 10.15K | 5.93M |
| Interest Expense | 495.00K | 6.30M | 10.88M | 10.88M | 18.08M | 14.39M | 13.49M | 8.23M | 9.43M | 7.21M | 5.30M | 492.00K | 2.10M | 2.51M | 50.00K | -212.00K | 376.00K | 405.55K | 96.10K |
| Depreciation & Amortization | 266.96M | 31.03M | 20.06M | 20.06M | 6.59M | 4.79M | 4.51M | 4.80M | 5.19M | 4.94M | 5.09M | 5.06M | 4.65M | 3.61M | 3.19M | 2.73M | 968.00K | 614.99K | 415.45K |
| EBITDA | -89.76M | -97.62M | -11.50M | -11.50M | -113.53M | -98.83M | -142.25M | -128.50M | -102.90M | -97.21M | -64.32M | -60.48M | -59.20M | -10.94M | -40.03M | -11.80M | -8.41M | -6.29M | 3.02M |
| EBITDA Ratio | -8,843.15% | -372.72% | -5.70% | -5.70% | -5,733.64% | -3,118.62% | -82,700.58% | -2,016.33% | -4,971.11% | -162,015.00% | 0.00% | -6,787.32% | -55,845.28% | -35.58% | -50.44% | -16.59% | -37.58% | -736.79% | 27,426,590.91% |
| Operating Income | -356.72M | -128.65M | -30.09M | -30.09M | -120.13M | -103.72M | -140.48M | -132.69M | -108.23M | -98.09M | -67.58M | -65.54M | -64.35M | -14.96M | -7.16M | -4.86M | -9.40M | -6.91M | -3.33M |
| Operating Income Ratio | -35,144.73% | -491.17% | -14.91% | -14.91% | -6,067.27% | -3,273.08% | -81,675.00% | -2,082.08% | -5,228.26% | -163,485.00% | 0.00% | -7,355.33% | -60,710.38% | -48.67% | -9.02% | -6.82% | -42.00% | -810.05% | -30,261,936.36% |
| Total Other Income/Expenses | 0.00 | -4.08M | -27.48M | -13.27M | -43.43M | -14.13M | -19.56M | -478.00K | -9.20M | -2.77M | -2.47M | -133.00K | -1.62M | -2.09M | 36.11M | 9.46M | 14.07M | 10.12M | -96.10K |
| Income Before Tax | -356.72M | -132.72M | -43.36M | -43.36M | -138.19M | -118.01M | -160.24M | -141.54M | -117.50M | -105.11M | -72.38M | -65.67M | -65.97M | -17.06M | -7.11M | -5.07M | -9.76M | -7.31M | 2.51M |
| Income Before Tax Ratio | -35,144.73% | -506.73% | -21.48% | -21.48% | -6,979.39% | -3,723.98% | -93,164.53% | -2,220.92% | -5,676.18% | -175,186.67% | 0.00% | -7,370.37% | -62,233.02% | -55.48% | -8.95% | -7.12% | -43.58% | -856.40% | 22,776,190.91% |
| Income Tax Expense | 10.31M | 6.22M | -32.82M | -32.82M | 32.82M | -6.00K | 19.56M | 8.85M | -26.00K | -4.25M | -2.33M | 267.00K | -7.00K | -1.00K | -36.16M | -9.25M | -14.07M | -10.12M | 96.10K |
| Net Income | -367.03M | -138.95M | -10.53M | -10.53M | -171.02M | -118.01M | -160.24M | -141.54M | -117.50M | -105.11M | -72.38M | -65.67M | -65.96M | -17.05M | -7.11M | -5.07M | -9.76M | -7.31M | 2.51M |
| Net Income Ratio | -36,160.59% | -530.49% | -5.22% | -5.22% | -8,637.37% | -3,723.79% | -93,164.53% | -2,220.92% | -5,676.18% | -175,186.67% | 0.00% | -7,370.37% | -62,226.42% | -55.48% | -8.95% | -7.12% | -43.58% | -856.40% | 22,776,190.91% |
| EPS | -2.23 | -0.93 | -0.07 | -0.08 | -1.75 | -1.40 | -2.66 | -2.75 | -2.40 | -2.38 | -1.96 | -2.19 | -2.73 | -0.85 | -0.38 | -0.28 | -0.56 | -0.42 | 0.14 |
| EPS Diluted | -2.23 | -0.93 | -0.07 | -0.08 | -1.75 | -1.40 | -2.66 | -2.75 | -2.40 | -2.38 | -1.96 | -2.19 | -2.73 | -0.85 | -0.38 | -0.28 | -0.56 | -0.42 | 0.14 |
| Weighted Avg Shares Out | 164.48M | 149.53M | 149.53M | 132.86M | 97.90M | 84.14M | 60.29M | 51.51M | 48.90M | 44.20M | 36.96M | 29.95M | 24.15M | 20.03M | 18.84M | 18.24M | 17.58M | 17.34M | 17.34M |
| Weighted Avg Shares Out (Dil) | 164.48M | 149.53M | 155.11M | 132.86M | 97.90M | 84.14M | 60.29M | 51.51M | 48.90M | 44.20M | 36.96M | 29.95M | 24.15M | 20.03M | 18.84M | 18.24M | 17.58M | 17.34M | 17.34M |
Source: https://incomestatements.info
Category: Stock Reports